As of May 25, 2025, Boston Scientific Corp (BSX) reports a EV/EBITDA of 40.36.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Boston Scientific Corp's EV/EBITDA to Peers
To better understand Boston Scientific Corp's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Boston Scientific Corp (BSX) | 40.36 |
| Penumbra Inc (PEN) | 170.72 |
| ABIOMED Inc (ABMD) | 89.47 |
| Intuitive Surgical Inc (ISRG) | 78.69 |
| Insulet Corp (PODD) | 60.29 |
| Dexcom Inc (DXCM) | 40.93 |
Compared to its competitors, Boston Scientific Corp's EV/EBITDA is among the highest compared to peers, suggesting the market values the company at a premium, possibly due to growth expectations.